Treatment with PTGS2 has been shown to reduce inflammation in rheumatoid arthritis rats by reducing serum levels of interleukin 1β, interleukin six and tumor necrosis factor α and their mRNA expression (Wei et al., 2020). This evidence concerns the gene PTGS2 and rheumatoid arthritis.